# Phase 1 Study of dmLT ID Vaccination in Healthy Adults

> **NCT02531685** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 100 (actual)

## Conditions studied

- Gastroenteritis Escherichia Coli

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

## Key facts

- **NCT ID:** NCT02531685
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-02
- **Primary completion:** 2020-05-04
- **Final completion:** 2020-05-04
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02531685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02531685, "Phase 1 Study of dmLT ID Vaccination in Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02531685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*